Treating hepatitis C in lower-income countries.
From the Division of Gastroenterology and Hepatology (C.R.J., M.H.N.) and the Department of Medicine (C.R.J., M.B., M.H.N.), Stanford University Medical Center; and the Center for Innovation in Global Health, Stanford University (M.B.) - both in Stanford, CA; and the Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN (L.R.R.).
Channa R
CR
Jayasekera
Michele
M
Barry
Lewis R
LR
Roberts
Mindie H
MH
Nguyen
D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D003906:Developing Countries; D016174:Hepacivirus; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D011480:Protease Inhibitors / Q000627:therapeutic use; D012324:RNA-Dependent RNA Polymerase / Q000037:antagonists & inhibitors
D000998:Antiviral Agents; D011480:Protease Inhibitors; D012324:RNA-Dependent RNA Polymerase